Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tommy Summe

Family Medicine Edmonds, WA Doctor of Osteopathy

NPI 1750393666 CMS profile 79717

7614 195Th St. S.W., Suite 200, Edmonds, WA 98026

Open in the dashboard

General payments

$12,578

622 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tommy Summe of Edmonds, WA is reported in the CMS Open Payments database as having received $12,578 across 622 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $277 14
2024 General $305 14
2023 General $1,104 51
2022 General $1,938 79
2021 General $2,489 121
2020 General $2,670 135
2019 General $3,794 208

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tommy Summe
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Tommy Summe were reported at $277. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Tommy Summe Family Medicine median Middle half National median
2019 $3,794 $150 $41–$543 $163
2020 $2,670 $120 $32–$415 $114
2021 $2,489 $137 $35–$551 $132
2022 $1,938 $137 $37–$512 $149
2023 $1,104 $149 $42–$545 $160
2024 $305 $156 $44–$560 $164
2025 $277 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Orexo US, Inc. $1,648 101 payments
  2. AstraZeneca Pharmaceuticals LP $1,639 65 payments
  3. Gilead Sciences, Inc. $1,144 42 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,108 60 payments
  5. Novo Nordisk Inc $960 45 payments
  6. Zyla Life Sciences $758 56 payments
  7. AbbVie, Inc. $752 26 payments
  8. Janssen Pharmaceuticals, Inc $592 23 payments
  9. Pfizer Inc. $408 17 payments
  10. Teva Pharmaceuticals USA, Inc. $390 38 payments
  11. Other $3,178 149 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,543 618 payments
  2. Education $35 4 payments
Products named General payments · program years 2019–2025
  1. Zubsolv $1,530 92 payments
  2. FARXIGA $772 29 payments
  3. SPRIX $696 49 payments
  4. XARELTO $525 22 payments
  5. BREZTRI $475 16 payments
  6. Saxenda $456 24 payments
  7. XIFAXAN $446 24 payments
  8. TRULANCE $399 25 payments
  9. UBRELVY $339 14 payments
  10. Vascepa $314 11 payments
  11. Other $6,933 341 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

622 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record